<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236921</url>
  </required_header>
  <id_info>
    <org_study_id>190051</org_study_id>
    <nct_id>NCT04236921</nct_id>
  </id_info>
  <brief_title>Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Bioequivalence Between DopaSnap® (Carbidopa/Levodopa 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet and to Evaluate the Food-Effect of DopaSnap® in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riverside Pharmacueticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riverside Pharmacueticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center, bioequivalence and food-effect, open-label study designed to be&#xD;
      conducted in three sequential parts:&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single center, bioequivalence and food-effect, open-label study designed to be&#xD;
      conducted in three sequential parts:&#xD;
&#xD;
        -  Part I: bioequivalence, food-effect, randomized, open-label, single dose, 3-period,&#xD;
           6-sequence, crossover design.&#xD;
&#xD;
        -  Part II: multiple-dose (every 4 hours), open-label, 1-period design.&#xD;
&#xD;
        -  Part III: multiple-dose (every 2 hours), open-label, 1-period design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part I: bioequivalence, food-effect, randomized, open-label, single-dose, 3-period, 6-sequence, crossover design.&#xD;
Part II: multiple-dose (every 4 hours), open-label, 1-period design.&#xD;
Part III: multiple-dose (every 2 hours), open-label, 1-period design. Subjects enrolled in Part II and Part III will be a subset of those who completed Part I.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Residual area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. T½ el</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Kel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Cmax</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Other</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x DopaSnap® tablet, administered under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x RLD of CD-LD tablet administered under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test - fed 1 x DopaSnap® tablet , administered under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DopaSnap®</intervention_name>
    <description>immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <other_name>test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDL of CD-LD</intervention_name>
    <description>(immediate release CD/LD 25/100mg; Merck Sharp &amp; Dohme Corp., USA),</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months&#xD;
             prior to screening), ≥35 and ≤75 years of age, with BMI &gt; 18.5 and &lt; 30.0 kg/m2 and&#xD;
             body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.&#xD;
&#xD;
          2. Healthy as defined by:&#xD;
&#xD;
               1. the absence of clinically significant illness and surgery within 4 weeks prior to&#xD;
                  dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated&#xD;
                  for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the&#xD;
                  Qualified Investigator.&#xD;
&#xD;
               2. the absence of clinically significant history of neurological, endocrinal,&#xD;
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic, and metabolic disease.&#xD;
&#xD;
          3. Females of childbearing potential who are sexually active with a male partner must be&#xD;
             willing to use one of the following acceptable contraceptive methods throughout the&#xD;
             study and for 30 days after the last study drug administration:&#xD;
&#xD;
               1. intra-uterine contraceptive device placed at least 4 weeks prior to study drug&#xD;
                  administration;&#xD;
&#xD;
               2. male condom with intravaginally applied spermicide starting at least 21 days&#xD;
                  prior to study drug administration;&#xD;
&#xD;
               3. hormonal contraceptives starting at least 4 weeks prior to study drug&#xD;
                  administration and must agree to use the same hormonal contraceptive throughout&#xD;
                  the study;&#xD;
&#xD;
               4. sterile male partner (vasectomized since at least 6 months).&#xD;
&#xD;
          4. Capable of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Any clinically significant abnormality at physical examination, clinically&#xD;
             significant abnormal laboratory test results or positive test for hepatitis B,&#xD;
             hepatitis C, or HIV found during medical screening.&#xD;
&#xD;
             2) Positive urine drug screen, alcohol breath test, or urine cotinine test at&#xD;
             screening.&#xD;
&#xD;
             3) History of allergic reactions to carbidopa, levodopa, or other related drugs, or to&#xD;
             any excipient in the formulation.&#xD;
&#xD;
             4) Positive pregnancy test at screening. 5) Clinically significant ECG abnormalities&#xD;
             or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg,&#xD;
             diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or&#xD;
             over 100 bpm) at screening.&#xD;
&#xD;
             6) History of significant alcohol abuse within 1 year prior to screening or regular&#xD;
             use of alcohol within 6 months prior to the screening visit (more than 14 units of&#xD;
             alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).&#xD;
&#xD;
             7) History of significant drug abuse within 1 year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and&#xD;
             amphetamine derivatives) within 1 year prior to screening.&#xD;
&#xD;
             8) Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to the first dosing,&#xD;
             administration of a biological product in the context of a clinical research study&#xD;
             within 90 days prior to the first dosing, or concomitant participation in an&#xD;
             investigational study involving no drug or device administration.&#xD;
&#xD;
             9) Use of medication other than topical drug products without significant systemic&#xD;
             absorption and hormonal contraceptives:&#xD;
&#xD;
               1. prescription medication within 14 days prior to the first dosing;&#xD;
&#xD;
               2. over-the-counter products and natural health products (including herbal remedies,&#xD;
                  homeopathic and traditional medicines, probiotics, food supplements such as&#xD;
                  vitamins, minerals, amino acids, essential fatty acids, and protein supplements&#xD;
                  used in sports) within 14 days prior to the first dosing, with the exception of&#xD;
                  the occasional use of acetaminophen (up to 2 g daily);&#xD;
&#xD;
               3. a depot injection or an implant of any drug within 3 months prior to the first&#xD;
                  dosing (other than hormonal contraceptives);&#xD;
&#xD;
               4. MAO inhibitors within 30 days prior to the first dosing; 10) Donation of plasma&#xD;
                  within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn&#xD;
                  at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL&#xD;
                  within 56 days prior to the first dosing.&#xD;
&#xD;
                  11) Hemoglobin &lt; 128 g/L (males) and &lt; 115 g/L (females) and hematocrit &lt; 0.36&#xD;
                  L/L (males) and &lt; 0.32 L/L (females) at screening.&#xD;
&#xD;
                  12) Any reason which, in the opinion of the Investigator, would prevent the&#xD;
                  subject from participating in the study.&#xD;
&#xD;
                  13) Breast-feeding subject. 14) History or presence of myasthenia gravis. 15)&#xD;
                  Treatment with centrally active drugs or those affecting peripheral cholinergic&#xD;
                  transmission within 3 months of screening.&#xD;
&#xD;
                  16) The presence of history of narrow angle glaucoma. 17) The presence of history&#xD;
                  of depression, suicidal tendencies, and other psychotic disorders.&#xD;
&#xD;
                  18) The presence of history of myocardial infarction, arrhythmias, bronchial&#xD;
                  asthma and other cardiovascular, or pulmonary disease.&#xD;
&#xD;
                  19) The presence of history of melanoma and suspicious undiagnosed skin lesions.&#xD;
&#xD;
                  20) The presence of history of neuroleptic malignant syndrome and non-traumatic&#xD;
                  rhabdomyolysis.&#xD;
&#xD;
                  21) The presence of history of peptic ulcer disease or undiagnosed recurrent&#xD;
                  gastro-intestinal bleeding.&#xD;
&#xD;
                  22) The presence of history of convulsions. 23) HAMD-7 score above 3 at&#xD;
                  screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Lamouche, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syneous Health</name>
      <address>
        <city>Québec</city>
        <state>Montreal</state>
        <zip>H3x 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

